Abstract is: Roxana Mehran is an Iranian-American cardiologist and Mount Sinai Endowed Professor of Medicine at the Icahn School of Medicine at Mount Sinai. She is known for her work in interventional cardiology.
| human | Q5 |
| P8179 | Canadiana Name Authority ID | ncf11527987 |
| P5243 | Canal-U person ID | mehran-roxana-254010601 |
| P6178 | Dimensions author ID | 015504030147.03 |
| P2671 | Google Knowledge Graph ID | /g/1hcqr45bg |
| P1960 | Google Scholar author ID | 11Q2EU8AAAAJ |
| P269 | IdRef ID | 254010601 |
| P244 | Library of Congress authority ID | n2007185346 |
| P496 | ORCID iD | 0000-0002-5546-262X |
| P214 | VIAF ID | 61005676 |
| P10832 | WorldCat Entities ID | E39PCjr8wQMWgXwHcDFvCK6G6q |
| P69 | educated at | St. George's University | Q7588178 |
| P108 | employer | Icahn School of Medicine at Mount Sinai | Q1950740 |
| P735 | given name | Roxana | Q3445675 |
| Roxana | Q3445675 | ||
| P106 | occupation | researcher | Q1650915 |
| cardiologist | Q3264451 | ||
| P21 | sex or gender | female | Q6581072 |
| Q51322991 | "Capturing" the Benefits of Dual-Therapy Stent Technology: Is This a Promise or Reality? |
| Q57025453 | 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration |
| Q34231154 | 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi |
| Q37953801 | 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiogr |
| Q61667402 | 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary |
| Q37953885 | 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi |
| Q57630066 | 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials |
| Q30882189 | 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardi |
| Q26779649 | 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA ... |
| Q34498935 | 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline |
| Q50084592 | 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways |
| Q52684480 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. |
| Q53081042 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. |
| Q123857375 | 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG |
| Q43284723 | 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents |
| Q46082433 | 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side B |
| Q91304723 | A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement |
| Q48912264 | A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? |
| Q37494353 | A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial |
| Q40607269 | A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study |
| Q46665850 | A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting |
| Q46280378 | A new score for risk stratification of patients with acute coronary syndromes undergoing percutaneous coronary intervention: the ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) risk score |
| Q33329008 | A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study |
| Q43166451 | A novel technique for ultra-low contrast administration during angiography or intervention |
| Q35907724 | A null mutation in ANGPTL8 does not associate with either plasma glucose or type 2 diabetes in humans |
| Q41983924 | A prospective natural-history study of coronary atherosclerosis |
| Q51219587 | A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". |
| Q84882777 | A provisional strategy for treating true bifurcation lesions employing a scoring balloon for the side branch: final results of the AGILITY trial |
| Q46503304 | A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial |
| Q43049810 | A risk score to predict bleeding in patients with acute coronary syndromes |
| Q28285964 | A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation |
| Q46000101 | A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. |
| Q50079459 | ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Su |
| Q50077736 | ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Sur |
| Q50223595 | ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Sur |
| Q57741455 | ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization |
| Q38017132 | ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: American College of Cardiology Foundation Appropriate Use Criteria Task Force Society for Cardiovascular Angiography and Interventi |
| Q38037246 | ACS and STEMI treatment: gender-related issues |
| Q53080726 | APPOSITION V: STENTYS coronary stent system clinical trial in subjects with ST-segment elevation myocardial infarction--rationale and design. |
| Q36245033 | Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients |
| Q45137335 | Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale |
| Q51793900 | Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis. |
| Q77439600 | Acute angiographic and clinical results of the NIR w/SOX stent |
| Q38086096 | Acute coronary syndromes: advances in antithrombotics |
| Q55306808 | Acute myocardial infarction in young women: current perspectives. |
| Q44830908 | Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model |
| Q38758001 | Advances in dual therapy stenting |
| Q86173031 | Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial |
| Q92529195 | Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study |
| Q53600197 | Age-related effects of smoking on coronary artery disease assessed by gray scale and virtual histology intravascular ultrasound. |
| Q51307280 | An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation. |
| Q80257706 | An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention |
| Q47876216 | An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries |
| Q89092895 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary interventio |
| Q41144806 | An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary interv |
| Q41960243 | Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial |
| Q42334342 | Anemia and Acute Coronary Syndrome: Time for Intervention Studies |
| Q46475076 | Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention |
| Q51545745 | Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study. |
| Q40458505 | Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). |
| Q31141831 | Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials |
| Q38281834 | Antiplatelet therapy after drug-eluting stent implantation |
| Q92440052 | Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation |
| Q90304894 | Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial |
| Q47204835 | Antithrombotic Treatment after Transcatheter Heart Valves Implant |
| Q39472608 | Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy |
| Q50496557 | Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. |
| Q38393483 | Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial |
| Q33446308 | Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry |
| Q38098754 | Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events |
| Q45093548 | Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial |
| Q37357501 | Are drug-eluting stents safe in the long term? |
| Q49114260 | Arterial hypertension: A neglected risk for bleeding |
| Q89423195 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention |
| Q81514556 | Assessing intermediate left main coronary lesions using intravascular ultrasound |
| Q93061032 | Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study) |
| Q51831131 | Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial). |
| Q86606555 | Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial |
| Q43098839 | Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis: The Multi-Ethnic BioImage Study |
| Q91142002 | Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial |
| Q34678771 | Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome |
| Q51111233 | Association of bleeding, mortality and sex in acute coronary syndromes: the missing triangle. |
| Q38639061 | Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study |
| Q52373769 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. |
| Q34974622 | Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial |
| Q47941404 | Atrial fibrillation, bleeding, and coronary intervention: current recommendations |
| Q46193167 | Autopsy validation study of the academic research consortium stent thrombosis definition |
| Q38460595 | B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial |
| Q38264835 | Balancing ischaemia and bleeding risks with novel oral anticoagulants |
| Q41751821 | Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). |
| Q34225132 | Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial |
| Q95555955 | Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI |
| Q46348115 | Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. |
| Q46648595 | Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis |
| Q41205746 | Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial |
| Q28281179 | Bivalirudin during primary PCI in acute myocardial infarction |
| Q28210982 | Bivalirudin for patients with acute coronary syndromes |
| Q28256871 | Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial |
| Q79971334 | Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial |
| Q38462854 | Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR- |
| Q33419676 | Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials |
| Q53151867 | Bleeding After Aortic Valve Replacement Matters: Important Mortality Risk. |
| Q39388995 | Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome |
| Q88995368 | Bleeding Severity After Percutaneous Coronary Intervention |
| Q53545902 | Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). |
| Q92855927 | Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes |
| Q53615664 | CABG Beats Vintage PCI: Does Contemporary PCI Stand a Chance to EXCEL? |
| Q58087845 | CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction |
| Q34574872 | Cardiological Society of India practice guidelines for angiography in patients with renal dysfunction |
| Q96293193 | Cardiovascular outcomes after percutaneous coronary intervention on bifurcation lesions with moderate to severe coronary calcium: A single-center registry study |
| Q47742326 | Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans |
| Q39438758 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). |
| Q48720669 | Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study |
| Q38413579 | Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial |
| Q52643133 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. |
| Q46982016 | Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). |
| Q43759546 | Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: implications for appropriate stent sizing |
| Q44856283 | Characteristics and outcomes of patients with ST-segment elevation myocardial infarction excluded from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial |
| Q47597302 | Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. |
| Q41640947 | Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions |
| Q45939638 | Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. |
| Q83444440 | Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture |
| Q95380844 | Classification for Assessing the Quality of Diagnostic Coronary Angiography |
| Q42822404 | Clinical Impact of Enhanced Inhibition of P2Y12-Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention |
| Q26799824 | Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium |
| Q53384591 | Clinical and angiographic evaluation of the resolute zotarolimus-eluting coronary stent in Japanese patients – long-term outcome in the RESOLUTE Japan and RESOLUTE Japan small vessel study. |
| Q46502924 | Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial |
| Q38371739 | Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial |
| Q36807166 | Clinical end points in coronary stent trials: a case for standardized definitions |
| Q45061501 | Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation |
| Q38029300 | Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study population |
| Q43856223 | Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure |
| Q91747798 | Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial |
| Q46834205 | Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings |
| Q46523338 | Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial |
| Q39117693 | Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial |
| Q38546453 | Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium |
| Q43911948 | Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel |
| Q50991247 | Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. |
| Q81448065 | Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction |
| Q34550040 | Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). |
| Q46904308 | Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy |
| Q40603186 | Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease |
| Q100513564 | Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents |
| Q46240416 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial |
| Q92572703 | Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study) |
| Q42883088 | Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-corona |
| Q40233986 | Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study). |
| Q60453532 | Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction With Versus Without Previous Coronary Artery Bypass Grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS- |
| Q38993152 | Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies |
| Q87414258 | Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction <40% versus ≥ 40% (from the HORIZONS-AMI trial) |
| Q47432784 | Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial). |
| Q82872483 | Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery |
| Q90779682 | Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration |
| Q34123999 | Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). |
| Q56982306 | Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial |
| Q44065287 | Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries |
| Q79838359 | Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age |
| Q52893063 | Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. |
| Q51806173 | Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥75 years of age versus those <75 years of age |
| Q75400017 | Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions |
| Q51837478 | Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients > or =80 years old versus those <80 years old. |
| Q53472865 | Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). |
| Q43510316 | Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers |
| Q73246222 | Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries |
| Q33413571 | Comparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). |
| Q44171159 | Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disea |
| Q51748167 | Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. |
| Q51027407 | Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study. |
| Q38971734 | Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy |
| Q51638776 | Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. |
| Q34137536 | Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization |
| Q51785128 | Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. |
| Q46873841 | Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes |
| Q40788384 | Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry |
| Q86965099 | Compensatory enlargement of the left main coronary artery: insights from the PROSPECT study |
| Q86451564 | Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial |
| Q44247305 | Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model |
| Q53358079 | Complex PCI: when the going gets tough the tough gets going. |
| Q88594462 | Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry |
| Q46060844 | Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry |
| Q45839848 | Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). |
| Q47673628 | Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). |
| Q38215340 | Contemporary overview and clinical perspectives of chronic total occlusions |
| Q39674875 | Contemporary practice patterns related to the risk of acute kidney injury in the catheterization laboratory: Results from a survey of Society of Cardiovascular Angiography and Intervention (SCAI) cardiologists |
| Q60453518 | Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy |
| Q43064438 | Contrast-induced acute kidney injury. Underappreciated or a new marker of cardiovascular mortality? |
| Q45201786 | Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables |
| Q36831201 | Contrast-induced nephropathy remains a serious complication of PCI. |
| Q37411900 | Contrast-induced nephropathy: prevention and management of high-risk patients |
| Q44781955 | Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis |
| Q41631482 | Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With Acute Coronary Syndrome: Analysis From the ACUITY Trial |
| Q96585739 | Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation |
| Q38886576 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. |
| Q62590244 | Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry |
| Q53639613 | Coronary artery revascularization in chronic kidney disease: time for a randomized trial. |
| Q51352499 | Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. |
| Q38003375 | Coronary pressure-derived fractional flow reserve measurements: recommendations for standardization, recording, and reporting as a core laboratory technique. Proposals for integration in clinical trials |
| Q44735169 | Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: findings from the HORIZONS-AMI trial |
| Q56985832 | Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options |
| Q39360380 | Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration |
| Q38614650 | Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial |
| Q46207733 | Correlation between index electrocardiographic patterns and pre-intervention angiographic findings: insights from the HORIZONS-AMI trial |
| Q38373654 | Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes in Patients With Right Coronary Artery ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: HORIZONS-AMI (The Harmonizing Outcom |
| Q73668666 | Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60% |
| Q47173746 | Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. |
| Q41333305 | Cost implications of intraprocedural thrombotic events during PCI. |
| Q45238081 | Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque |
| Q63185714 | Cuestiones relativas al sexo en cardiología intervencionista: declaración de consenso de la iniciativa Women in Innovations (WIN) |
| Q38214839 | Current challenges for clinical trials of cardiovascular medical devices |
| Q49582739 | Current evidence for the safety and efficacy of the bio-engineered dual therapy COMBO stent |
| Q38095795 | Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies |
| Q47833058 | D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy |
| Q53287669 | DAPT duration after DES: what is the "mandatory" duration? |
| Q89432741 | Debris Heterogeneity Across Different Valve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement |
| Q51741704 | Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. |
| Q44284349 | Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model |
| Q93053801 | Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology |
| Q92665542 | Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention |
| Q51749911 | Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. |
| Q39515673 | Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes |
| Q42332217 | Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy |
| Q43986424 | Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). |
| Q44464832 | Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk |
| Q53593071 | Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. |
| Q87447221 | Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study |
| Q42167544 | Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing |
| Q53367698 | Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. |
| Q51529469 | Drug-eluting stents and drug-eluting balloons are the best strategies to treat coronary in-stent restenosis. |
| Q98473098 | Drug-eluting stents in diabetic patients: Are we still treading water? |
| Q37301358 | Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome |
| Q40319620 | Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials |
| Q57132788 | Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry) |
| Q61651386 | Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents |
| Q38137724 | Dual antiplatelet therapy dilemmas: duration and choice of antiplatelets in acute coronary syndromes |
| Q26799079 | Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence |
| Q26852886 | Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials |
| Q44053651 | Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial |
| Q38392725 | Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials |
| Q47722656 | Early Ventricular Tachycardia or Fibrillation in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention and Impact on Mortality and Stent Thrombosis (from the Harmonizing Outcomes with Revascularizatio |
| Q43736088 | Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial |
| Q37405670 | Echocardiography-guided interventions |
| Q46236048 | Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes |
| Q90684188 | Effect of Baseline Anemia on Outcomes After Left Main Coronary Revascularization |
| Q33425641 | Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention |
| Q40112204 | Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials |
| Q50188567 | Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative |
| Q40996247 | Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). |
| Q52650835 | Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. |
| Q38380117 | Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial |
| Q39462063 | Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). |
| Q51031387 | Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). |
| Q47338535 | Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy |
| Q40300202 | Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). |
| Q44108396 | Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection |
| Q93079964 | Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration |
| Q84257672 | Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis |
| Q38400558 | Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial |
| Q46711890 | Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis |
| Q46672411 | Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study). |
| Q47297262 | Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials |
| Q33431313 | Effects of baseline and early acquired thrombocytopaenia on long-term mortality in patients undergoing percutaneous coronary intervention with bivalirudin |
| Q49389477 | Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis |
| Q38781681 | Efficacy and safety of routine thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and meta-analysis of randomized controlled trials |
| Q34218558 | Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). |
| Q50148886 | Equal sex-based outcomes in unprotected left main PCI: No advantage for men. |
| Q44161865 | Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model |
| Q27004466 | Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC) |
| Q38390108 | Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolim |
| Q40391829 | Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort |
| Q50725684 | Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. |
| Q39492381 | Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease |
| Q83895113 | Evidence based management of patients undergoing PCI. Conclusion |
| Q37718106 | Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury |
| Q102373871 | Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry |
| Q45071322 | Exome-wide association study of plasma lipids in >300,000 individuals |
| Q38162397 | Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions |
| Q51654770 | Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes. |
| Q51818674 | Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). |
| Q51393862 | Female gender and mortality after percutaneous coronary intervention: results from a large registry. |
| Q47573490 | Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients |
| Q51058537 | Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. |
| Q50531598 | Fibrous Cap Thickness by Optical Coherence Tomography In Vivo. |
| Q46196466 | First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter |
| Q44803696 | First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial |
| Q46533338 | First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial |
| Q90342373 | Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease |
| Q38402937 | Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. |
| Q35548361 | Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes |
| Q45395198 | Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction |
| Q51644555 | Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. |
| Q86403242 | Frequency, mechanisms, and implications of late peri-stent contrast staining: analysis (from the HORIZONS-AMI Trial) |
| Q35552554 | From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. |
| Q35558849 | From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. |
| Q51707931 | Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. |
| Q42634785 | Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial |
| Q37583092 | Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes |
| Q39438763 | Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes |
| Q43957429 | Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors |
| Q51305480 | Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. |
| Q34556502 | Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILL |
| Q38602893 | Gender differences in outcomes in patients with acute coronary syndrome in the current era: A review |
| Q44734734 | Gender outcomes in acute myocardial infarction: are women from Venus and men from Mars? |
| Q63185715 | Gender-Based Issues in Interventional Cardiology: a Consensus Statement from the Women in Innovations (WIN) Initiative |
| Q51590029 | Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) Initiative. |
| Q39902448 | Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative |
| Q51498937 | Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. |
| Q41654886 | Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes |
| Q46883865 | Gender-specific outcomes after sirolimus-eluting stent implantation |
| Q37682697 | Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease |
| Q92315017 | Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry |
| Q50146799 | Guidelines for Patient-Reported Outcomes in Clinical Trial Protocols |
| Q67223888 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q92291004 | Hope for the best, prepare for the worst: How to manage coronary perforations |
| Q90275449 | Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial |
| Q37888541 | How serious a problem is bleeding in patients with acute coronary syndromes? |
| Q45930084 | Hydration protocols to reduce the incidence of contrast-induced nephropathy. |
| Q51384405 | Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. |
| Q40774686 | Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study |
| Q45064792 | Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study |
| Q41021567 | Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). |
| Q47929076 | Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction |
| Q40736980 | Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Dr |
| Q40102186 | Impact of Contrast Dose Reduction on Incidence of Acute Kidney Injury (AKI) Among Patients Undergoing PCI: A Modeling Study |
| Q34486268 | Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials |
| Q91748345 | Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents |
| Q40319115 | Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention |
| Q38378830 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention |
| Q46262291 | Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). |
| Q57412725 | Impact of Major Bleeding on Long-Term Mortality in Anemic Versus Nonanemic Patients Undergoing Percutaneous Coronary Intervention Using Bivalirudin |
| Q90348560 | Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study) |
| Q50064019 | Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical Outcome in Patients With Acute Coronary Syndromes: An Analysis From the PROSPECT Study |
| Q47785646 | Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial |
| Q91040575 | Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study |
| Q85998502 | Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial |
| Q50662100 | Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibiti |
| Q51618206 | Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. |
| Q43069516 | Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). |
| Q46368065 | Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions |
| Q41430853 | Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial |
| Q51783108 | Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. |
| Q44297604 | Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). |
| Q40222868 | Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). |
| Q33394100 | Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HO |
| Q53664647 | Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial I |
| Q50927564 | Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery. |
| Q42932164 | Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial |
| Q52567416 | Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: Insights from the HORIZONS-AMI trial. |
| Q33369671 | Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction |
| Q91218265 | Impact of calcification on percutaneous coronary intervention: MACE-Trial 1-year results |
| Q84353023 | Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial |
| Q43288786 | Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage str |
| Q44994395 | Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention |
| Q46212297 | Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). |
| Q47279192 | Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction |
| Q90240334 | Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry |
| Q51329510 | Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study). |
| Q53597769 | Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. |
| Q44036065 | Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial |
| Q43723574 | Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). |
| Q51541059 | Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. |
| Q84582293 | Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute M |
| Q38376058 | Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial |
| Q46030224 | Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). |
| Q40952288 | Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial |
| Q44260544 | Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. |
| Q57169159 | Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents |
| Q91266467 | Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy |
| Q84572937 | Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial |
| Q28186862 | Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction |
| Q85090019 | Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t |
| Q38049079 | Impact of in-hospital major bleeding on outcomes in acute coronary syndromes |
| Q38453848 | Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial |
| Q90257344 | Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI |
| Q43918642 | Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents |
| Q51674430 | Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. |
| Q56985462 | Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction t |
| Q39639977 | Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial |
| Q51758758 | Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. |
| Q46843183 | Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial |
| Q30398247 | Impact of multiple complex plaques on short- and long-term clinical outcomes in patients presenting with ST-segment elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORI |
| Q40205533 | Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction |
| Q83795968 | Impact of myocardial bridge on clinical outcome after coronary stent placement |
| Q41963433 | Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy). |
| Q53936363 | Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. |
| Q51531268 | Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). |
| Q92217180 | Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial |
| Q56334747 | Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation |
| Q46496318 | Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). |
| Q43709119 | Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents |
| Q51704345 | Impact of pre-procedural cardiopulmonary instability in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction T |
| Q38938320 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry |
| Q44668975 | Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction |
| Q40310743 | Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial |
| Q84817753 | Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial) |
| Q51375652 | Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. |
| Q93141850 | Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry |
| Q51562214 | Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). |
| Q75351724 | Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions |
| Q53364967 | Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. |
| Q34021163 | Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials |
| Q34637924 | Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial |
| Q44945169 | Impact of the severity of coronary artery calcification on clinical events in patients undergoing coronary artery bypass grafting (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). |
| Q45982712 | Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. |
| Q46176948 | Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). |
| Q39278248 | Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial |
| Q42844493 | Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). |
| Q51179156 | Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. |
| Q43886892 | Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial |
| Q87447501 | Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury "downstream of downstream" |
| Q47743584 | Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial |
| Q53225036 | Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. |
| Q83384848 | In vivo intravascular ultrasonic assessment of anomalous right coronary artery arising from left coronary sinus |
| Q37812440 | In-stent restenosis in the drug-eluting stent era. |
| Q44067510 | Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction |
| Q33394098 | Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial |
| Q39579404 | Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI |
| Q39579411 | Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction |
| Q43443221 | Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial |
| Q38885545 | Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry |
| Q41445718 | Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention |
| Q38924633 | Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). |
| Q57243383 | Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention |
| Q88461145 | Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis |
| Q38500556 | Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revasculariza |
| Q92738575 | Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry |
| Q38426910 | Incidence, predictors, and impact of neurological events in non-ST-segment elevation acute coronary syndromes: the ACUITY trial |
| Q38428199 | Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial |
| Q44684605 | Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study |
| Q91836449 | Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology |
| Q47225900 | Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial |
| Q91433521 | Influence of Final Kissing Balloon Inflation on Long-term Outcomes After PCI of Distal Left Main Bifurcation Lesions: Analysis From the EXCEL Trial |
| Q28171094 | Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction |
| Q51496377 | Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study). |
| Q34982591 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization |
| Q51538691 | Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. |
| Q48564880 | International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies |
| Q43500037 | Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes |
| Q52812208 | Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study. |
| Q41203311 | Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes |
| Q38474127 | Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial |
| Q38443687 | Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial |
| Q33959229 | Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model |
| Q34638192 | Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervent |
| Q73438377 | Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions |
| Q40410810 | Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts |
| Q83297062 | Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts |
| Q84077211 | Intravascular ultrasound assessment of cobalt chromium versus stainless steel drug-eluting stent expansion |
| Q45253566 | Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation |
| Q84768530 | Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation |
| Q79279183 | Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes |
| Q43144683 | Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located? |
| Q57213766 | Intravascular ultrasound comparison of left main coronary artery disease between white and Asian patients |
| Q38490870 | Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy |
| Q42883082 | Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents |
| Q80960386 | Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques |
| Q58293663 | Intravascular-ultrasound-guided percutaneous transluminal coronary angioplasty/provisional stent implantation strategy: impact on long-term clinical follow-up |
| Q119953326 | Invasive Versus Medical Management in Patients With Chronic Kidney Disease and Non–ST‐Segment–Elevation Myocardial Infarction |
| Q37122647 | Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions |
| Q46000107 | Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chroni |
| Q40996236 | Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). |
| Q43117188 | Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible? |
| Q40783276 | Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial |
| Q51752013 | Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheteri |
| Q89182594 | Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-e |
| Q56334207 | Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial |
| Q57243355 | Letter by Mehran et al Regarding Article, “Bleeding Academic Research Consortium Consensus Report: The Food and Drug Administration Perspective” |
| Q38443693 | Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial |
| Q58594778 | Limitations of Current Risk Scoring in Real World Populations: The Importance of External Validation |
| Q57764234 | Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry |
| Q91834766 | Long-Term Outcomes After Revascularization for Stable Ischemic Heart Disease: An Individual Patient-Level Pooled Analysis of 19 Randomized Coronary Stent Trials |
| Q91783281 | Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention |
| Q38704416 | Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration |
| Q46810032 | Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 years): five-year outcomes from a 1,791 patient multi-national registry |
| Q43828001 | Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery diseas |
| Q51213062 | Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary art |
| Q57214404 | Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with versus without diabetes mellitus |
| Q38474268 | Long-term follow-up of attenuated plaques in patients with acute myocardial infarction: an intravascular ultrasound substudy of the HORIZONS-AMI trial |
| Q73727652 | Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III) |
| Q84974281 | Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocard |
| Q43605422 | Long-term outcome of percutaneous coronary intervention for chronic total occlusions |
| Q46828858 | Long-term outcomes of percutaneous coronary interventions or coronary artery bypass grafting for left main coronary artery disease in octogenarians (from a Drug-Eluting stent for LefT main Artery registry substudy). |
| Q44021447 | Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial). |
| Q45240001 | Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions |
| Q45938698 | Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). |
| Q91615772 | Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review |
| Q38373158 | Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia |
| Q38398190 | Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome |
| Q51689831 | Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. |
| Q45287676 | Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery |
| Q41004668 | Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial |
| Q92747998 | Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial |
| Q38896447 | Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters |
| Q43168420 | Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies |
| Q43188478 | N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question |
| Q46727655 | Necrotic core and its ratio to dense calcium are predictors of high-risk non-ST-elevation acute coronary syndrome |
| Q49351089 | Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement: Insights From the SENTINEL Trial |
| Q38986493 | Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q35190937 | New approaches to preventing restenosis |
| Q74317542 | New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry |
| Q53434126 | New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction: a propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale AngiopLastiche Dell'Emilia-Romagna). |
| Q98222208 | Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management |
| Q51224812 | Non-fibroatheroma lesion phenotype and long-term clinical outcomes: a substudy analysis from the PROSPECT study. |
| Q50927625 | Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. |
| Q45158732 | Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation |
| Q101472843 | One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients |
| Q96027338 | One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents |
| Q38951997 | One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study |
| Q89891542 | Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis |
| Q57797456 | Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting |
| Q39751797 | Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis |
| Q43585011 | Optimal catchment area and primary PCI centre volume revisited: a single-centre experience in transition from high-volume centre to "mega centre" for patients with ST-segment elevation myocardial infarction |
| Q44650101 | Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries |
| Q51150191 | Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. |
| Q28212485 | Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial |
| Q43413010 | Outcome of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention during on- versus off-hours (a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS- |
| Q53215061 | Outcomes After Successful Percutaneous Coronary Intervention of Calcified Lesions Using Rotational Atherectomy, Cutting-Balloon Angioplasty, or Balloon-Only Angioplasty Before Drug-Eluting Stent Implantation. |
| Q43524250 | Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial) |
| Q34982415 | Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial |
| Q45979909 | Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis. |
| Q43652562 | Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: results from the INFUSE-AMI study |
| Q47312318 | Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials |
| Q87445716 | Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial) |
| Q51806166 | Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). |
| Q51823603 | Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. |
| Q51498928 | Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. |
| Q41746603 | Outcomes of patients calling emergency medical services for suspected acute cardiovascular disease |
| Q51373166 | Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [ |
| Q43287139 | Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials |
| Q34642825 | Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial |
| Q51498954 | Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. |
| Q51498947 | Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. |
| Q38307962 | PCI and CABG surgery in 2014: CABG surgery versus PCI in CAD--surgery strikes again! |
| Q47908774 | Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials |
| Q38493997 | Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial |
| Q44546500 | Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction |
| Q58592697 | Paravalvular Leak: An Interesting Interplay of Acquired vWF-Disease and Late Bleeding After TAVR |
| Q53311236 | Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. |
| Q90908067 | Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes |
| Q38938312 | Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry |
| Q35590871 | Patterns of caregiving among patients hospitalized with cardiovascular disease |
| Q38376910 | Percutaneous Coronary Intervention of Saphenous Vein Graft |
| Q44585944 | Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association |
| Q47711302 | Percutaneous coronary intervention of bifurcation lesions and platelet reactivity |
| Q49972170 | Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study |
| Q38076852 | Percutaneous recanalization of chronic total occlusions: wherein lies the body of proof? |
| Q36282753 | Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. |
| Q36288750 | Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. |
| Q36254967 | Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results |
| Q55018355 | Photoplethysmography using a smartphone application for assessment of ulnar artery patency: a randomized clinical trial. |
| Q51406020 | Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). |
| Q38379501 | Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). |
| Q89125284 | Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study |
| Q47855555 | Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection |
| Q41968141 | Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study |
| Q38380488 | Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting |
| Q40980235 | Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial |
| Q89679903 | Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk |
| Q53626125 | Polymer-free stents in diabetic patients-not so sweet after all! |
| Q35822581 | Post-market approval surveillance: a call for a more integrated and comprehensive approach |
| Q47428805 | Postmarket evaluation of breakthrough technologies |
| Q36395936 | Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach |
| Q85345619 | Postprocedural anticoagulation for specific therapeutic indications after revascularization for ST-segment elevation myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial) |
| Q43897723 | Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention |
| Q90229507 | Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study |
| Q38430544 | Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction |
| Q38194737 | Pre-eclampsia and future cardiovascular risk among women: a review |
| Q30276130 | Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer |
| Q39619295 | Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials |
| Q57818728 | Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population |
| Q51485784 | Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. |
| Q85209593 | Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial |
| Q41496097 | Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI. |
| Q39728039 | Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). |
| Q56983614 | Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial |
| Q50067610 | Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). |
| Q45100441 | Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). |
| Q40161912 | Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials |
| Q91253651 | Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: Analysis from the HORIZONS-AMI trial |
| Q38375896 | Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy |
| Q44614140 | Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial |
| Q38454235 | Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial |
| Q41005834 | Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials |
| Q38410176 | Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry |
| Q48103275 | Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. |
| Q38886594 | Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study |
| Q99633305 | Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing TAVI for severe aortic stenosis: Insights from the WIN-TAVI registry |
| Q37587484 | Prevention and treatment of contrast-associated nephropathy in interventional cardiology |
| Q40427390 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. |
| Q50645391 | Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. |
| Q96586604 | Procedural and 1-year clinical outcomes of orbital atherectomy for treatment of coronary in-stent restenosis: A single-center, retrospective study |
| Q53665698 | Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. |
| Q38429943 | Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial |
| Q97532755 | Prognostic Impact of Race in Patients Undergoing PCI: Analysis From 10 Randomized Coronary Stent Trials |
| Q49543173 | Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin) ± Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention |
| Q83221765 | Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial |
| Q50602241 | Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. |
| Q84682483 | Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial |
| Q50536022 | Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study. |
| Q46974550 | Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction |
| Q38376864 | Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial |
| Q80193954 | Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions |
| Q43985199 | Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial |
| Q38475716 | Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial |
| Q45921756 | Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Interven |
| Q44445342 | Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial |
| Q84613750 | Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention |
| Q46318609 | Prognostic utility of the SYNTAX score in patients with single versus multivessel disease undergoing percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial). |
| Q38212318 | Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis |
| Q46517038 | Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). |
| Q54114442 | Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. |
| Q51065444 | Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry. |
| Q39039443 | Prosthetic Heart Valve Thrombosis |
| Q44599011 | Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement |
| Q38402115 | Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study |
| Q45962756 | Pursuit of perfection: three-dimensional CT angiographic "objective quantification" of aortic valve structures for transcatheter aortic valve implantation. |
| Q42201341 | Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score |
| Q40103494 | Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). |
| Q77480632 | Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation |
| Q50154495 | Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial |
| Q48556144 | Radial artery occlusion: preventing insult to injury |
| Q90964856 | Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial |
| Q35056263 | Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function |
| Q50848011 | Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. |
| Q51728754 | Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). |
| Q46953790 | Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial |
| Q90779637 | Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis |
| Q51472193 | Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acu |
| Q48657684 | Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic c |
| Q92773863 | Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy |
| Q46154973 | Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry |
| Q52321211 | Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions. |
| Q85763381 | Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index |
| Q37606723 | Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy |
| Q91304729 | Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement |
| Q39492390 | Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). |
| Q40806431 | Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study |
| Q39618366 | Relation between angiographic lesion severity, vulnerable plaque morphology and future adverse cardiac events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study). |
| Q46966155 | Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Ste |
| Q40222862 | Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty |
| Q51842734 | Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. |
| Q40252817 | Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardia |
| Q88084180 | Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT Study) |
| Q51689829 | Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. |
| Q90666866 | Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents |
| Q93168012 | Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization |
| Q53110907 | Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report. |
| Q37599602 | Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial |
| Q85614047 | Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy |
| Q83785783 | Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy |
| Q79743331 | Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction |
| Q104793527 | Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study |
| Q38440568 | Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study |
| Q47222373 | Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial |
| Q44640403 | Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction |
| Q38665263 | Reperfusion strategies in acute myocardial infarction and multivessel disease |
| Q50139192 | Reply: Chronic Kidney Disease and Antiplatelet Therapy: A Worrying Gap Between Evidence Based Medicine and Clinical Practice |
| Q54420705 | Reply: Last Nail in the Coffin for Propensity Scores in Observational Cardiovascular Studies? |
| Q49710638 | Reply: Research and Therapeutic Nihilisms in Chronic Kidney Disease |
| Q54392159 | Reply: Risk Scores From PARIS Registry: Are They Useful in a Contemporary Cohort of ACS Patients? |
| Q61671016 | Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary |
| Q39639374 | Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention |
| Q40752196 | Resistant in-stent restenosis in the drug eluting stent era. |
| Q51462278 | Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study". |
| Q33428812 | Revascularization Strategies for Calcified Lesions in Patients Presenting With Acute Coronary Syndromes (From the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). |
| Q38153784 | Revascularization strategies in patients with Type 2 diabetes mellitus |
| Q31155926 | Risk of contrast-induced acute kidney injury in ST-elevation myocardial infarction patients undergoing multi-vessel intervention-meta-analysis of randomized trials and risk prediction modeling study using observational data |
| Q38093948 | Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review |
| Q48954147 | Risk stratification of patients undergoing medical therapy after coronary angiography |
| Q45969326 | Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention. |
| Q43268517 | Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial |
| Q38399421 | Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial |
| Q43511520 | SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel |
| Q37829515 | SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel |
| Q50733260 | STEMI with multivessel disease: An ongoing battle for the optimal treatment strategy. |
| Q53641520 | SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy. |
| Q39693560 | SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements |
| Q92874778 | Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials |
| Q39764608 | Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials |
| Q98508846 | Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis |
| Q60453545 | Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction |
| Q40812182 | Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis |
| Q40126785 | Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis |
| Q37488452 | Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). |
| Q46627427 | Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial |
| Q91756914 | Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention |
| Q46405334 | Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Interventio |
| Q53057713 | Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. |
| Q46529943 | Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials |
| Q50176817 | Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents |
| Q34775547 | Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and |
| Q51100565 | Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. |
| Q46510109 | Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial |
| Q46090924 | Safety and performance of targeted renal therapy: the Be-RITe! Registry |
| Q37760031 | Safety issues related to treating bifurcation lesions. |
| Q28199516 | Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study |
| Q51774226 | Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial. |
| Q45171307 | Same or next day discharge: A new chapter in transcatheter aortic valve implantation |
| Q48452886 | Seizure-related takotsubo cardiomyopathy in a patient with recurrent malignant meningioma |
| Q85121343 | Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial |
| Q83199641 | Serial intravascular ultrasound analysis of the impact of myocardial bridge on neointimal proliferation after coronary stenting in patients with acute myocardial infarction |
| Q39944702 | Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials |
| Q114255013 | Sex Differences in Cardiovascular Research: A Scientometric Analysis |
| Q38380899 | Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). |
| Q90554791 | Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration |
| Q50229683 | Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study |
| Q41702442 | Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). |
| Q38801295 | Sex-Based Differences in Acute Coronary Syndromes: Insights From Invasive and Noninvasive Coronary Technologies |
| Q39619291 | Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents |
| Q39071281 | Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. |
| Q51121376 | Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. |
| Q38938316 | Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study |
| Q36102874 | Sharing Data from Cardiovascular Clinical Trials--A Proposal |
| Q46834201 | Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. |
| Q51687151 | Short- and long-term results after multivessel stenting in diabetic patients. |
| Q57097296 | Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease |
| Q39592831 | Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials |
| Q38212978 | Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome? |
| Q50982745 | Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. |
| Q47853413 | Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial |
| Q91151623 | Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies |
| Q33497692 | Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis |
| Q38579536 | Stable coronary artery disease: revascularisation and invasive strategies |
| Q95579885 | Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document |
| Q89068786 | Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document |
| Q57916616 | Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials |
| Q37889006 | Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium |
| Q89542398 | Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC) |
| Q34492675 | Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium |
| Q37643905 | Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group |
| Q38195452 | State of the art contemporary treatment of patients with ST elevation myocardial infarction: pre- and in-hospital organization, devices and drugs |
| Q35633916 | Statin use prior to angiography for the prevention of contrast-induced acute kidney injury: a meta-analysis of 19 randomised trials |
| Q91213493 | Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial |
| Q43530549 | Stent apposition in late and very late stent thrombosis: the apposing views |
| Q44055095 | Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial |
| Q38262362 | Stent thrombosis: a clinical perspective |
| Q46420633 | Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study |
| Q89711644 | Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention |
| Q38495932 | Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocard |
| Q51577658 | Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. |
| Q38410814 | Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with non-ST-segment-elevation acute coronary syndrome: analysis from the Acute Catheterization and Early Intervention Triage Strategy trial |
| Q42851156 | Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial |
| Q47207708 | TAVR technology-size matters! |
| Q63185707 | TCT-326 The Occupational Effects of Interventional Cardiology Results from the WIN for Safety Survey |
| Q61793961 | TCT-593 Gender Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From TWENTE and DUTCH PEERS |
| Q51369325 | Target lesion failure with BRS? good old DES to the rescue. |
| Q46514295 | The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale |
| Q38564027 | The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction |
| Q45935378 | The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. |
| Q53468749 | The OPERA study: the tenor or baritone of shorter duration of DAPT? |
| Q34334903 | The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent |
| Q90727145 | The Risk / Benefit Tradeoff of Antithrombotic Therapy in Patients with Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS |
| Q48901653 | The SYNTAX Score Does Not Predict Risk of Adverse Events in Patients With Non-ST Elevation Acute Coronary Syndrome Who Undergo Coronary Artery Bypass Graft Surgery |
| Q42626606 | The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial |
| Q95623283 | The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial |
| Q33933268 | The bleeding risk score as a mortality predictor in patients with acute coronary syndrome |
| Q38603459 | The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review |
| Q38439997 | The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial |
| Q90979103 | The obesity paradox revisited: body mass index and -long-term outcomes after PCI from a large pooled patient-level database |
| Q51301886 | The occupational effects of interventional cardiology: results from the WIN for Safety survey. |
| Q57796301 | The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry |
| Q37599599 | The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial |
| Q43276411 | The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions. |
| Q35171837 | The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study |
| Q84149231 | The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) t |
| Q43202648 | The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. |
| Q45361719 | The time dependence of antithrombin initiation in patients with non-ST-segment elevation acute coronary syndromes: subgroup analysis from the ACUITY trial |
| Q28222669 | The truth and consequences of the COURAGE trial |
| Q40315261 | The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention |
| Q37402192 | The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study |
| Q43608543 | Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study |
| Q47903684 | Thrombo-embolic prevention after transcatheter aortic valve implantation |
| Q36419388 | Thrombosis after implantation of drug-eluting stents. |
| Q53928329 | Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. |
| Q38886590 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study |
| Q38886583 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry |
| Q104286248 | Towards a standardized classification of cardiogenic shock: Will the new SCAI staging system translate into better clinical practice and research? |
| Q91616328 | Transcatheter Cardiovascular Therapeutics 2018 |
| Q101407110 | Transcatheter aortic valve replacement in patients with end-stage renal disease: Is "better than nothing" good enough? |
| Q51157749 | Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. |
| Q46911870 | Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. |
| Q40454454 | Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. |
| Q38239055 | Trials of implantable monitoring devices in heart failure: which design is optimal? |
| Q50979607 | Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. |
| Q83078618 | Two-year safety and effectiveness of sirolimus-eluting stents (from a prospective registry) |
| Q35605397 | Understanding the consequences of contrast-induced nephropathy |
| Q92772229 | Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention |
| Q34644302 | Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document |
| Q95423935 | Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document |
| Q87396274 | Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document |
| Q87410383 | Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document |
| Q38048557 | Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). |
| Q37465644 | Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis |
| Q91105693 | Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes |
| Q38886570 | Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study |
| Q78772918 | Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention |
| Q51842738 | Usefulness of beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts. |
| Q82686930 | Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy) |
| Q41223745 | Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy). |
| Q41267503 | Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With R |
| Q51752078 | Usefulness of the SYNTAX score to predict acute kidney injury after percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). |
| Q47393557 | Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy |
| Q47412323 | Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial). |
| Q38391491 | Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials |
| Q47998899 | Valvular Heart Disease in Women, Differential Remodeling, and Response to New Therapies |
| Q36052987 | Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques |
| Q35885937 | Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis |
| Q80845993 | Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound |
| Q38378126 | Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy |
| Q51098019 | Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis. |
| Q30586019 | We are 'shocked', 'frozen', and 'freed' by new data |
| Q38008146 | What is the optimal antithrombotic strategy in primary percutaneous coronary intervention? |
| Q46085914 | When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Compl |
| Q40955307 | Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?: A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials |
| Q50061984 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). |
| Q47751323 | Women in Interventional Cardiology: Past, Present, and Future-Small Numbers, Growing Impact |
| Q30985988 | Women in interventional cardiology: Update in percutaneous coronary intervention practice patterns and outcomes of female operators from the National Cardiovascular Data Registry®. |
| Q53200639 | Worsening atrioventricular conduction after hospital discharge in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the HORIZONS-AMI trial. |
| Q28252529 | 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi |
| Roxana Mehran | wikipedia | |
| Persian (fa / Q9168) | رکسانا مهران | wikipedia |
Search more.